Leukemia, Myeloid

• 

  Subject Areas on Research

  • 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. 
  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 
  • A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. 
  • A marker chromosome abnormality. Occurrence in chloramphenicol-associated acute leukemia. 
  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. 
  • Abdominal pain and a pelvic mass. 
  • Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. 
  • Acute leukemia following treatment of malignant glioma. 
  • Acute myeloid leukemia clinical practice guidelines in oncology. 
  • Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions. 
  • Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. 
  • Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. 
  • Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. 
  • Allogeneic marrow transplantation. 
  • Altered cytoplasmic/nuclear distribution of the c-myc protein in differentiating ML-1 human myeloid leukemia cells. 
  • An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B. 
  • Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. 
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 
  • Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. 
  • BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. 
  • BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Chemotactic peptide receptor-cytoskeletal interactions and functional correlations in differentiated HL-60 cells and human polymorphonuclear leukocytes. 
  • Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. 
  • Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. 
  • Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. 
  • Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. 
  • Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. 
  • Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin. 
  • Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. 
  • Current concepts. Cancer in children. 
  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 
  • Detecting treatment-by-centre interaction in multi-centre clinical trials. 
  • Detection of both T-cell and Ia-like antigens on cells from patients with acute myelomonocytic leukemia and chronic myelogenous leukemia in blast crisis. 
  • Diagnosis and management of myeloproliferative disorders. 
  • Diagnosis of posttransplant granulocytic sarcoma by fine-needle aspiration cytology and flow cytometry. 
  • Dibutyryl cyclic adenosine monophosphate reduces expression of c-myc during HL-60 differentiation. 
  • Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. 
  • Differential apoptosis-inducing effect of quercetin and its glycosides in human promyeloleukemic HL-60 cells by alternative activation of the caspase 3 cascade. 
  • Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. 
  • Disseminated Nocardia caviae with positive blood cultures. 
  • Distinction between alkaline phosphatase and Mg2+-ATPase of the human polymorphonuclear leukocyte. 
  • Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. 
  • Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). 
  • Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. 
  • Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. 
  • Erythrophagocytosis by dysplastic neutrophils in chronic myelomonocytic leukemia and subsequent transformation to acute myeloid leukemia. 
  • Essential amino acid deprivation induces monocytic differentiation of the human HL-60 myeloid leukemia cell line. 
  • Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. 
  • Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML). 
  • Fatal, disseminated Acremonium strictum infection in a neutropenic host. 
  • Graft-versus-leukemia in the rat--the antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease. 
  • Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. 
  • Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. 
  • Granulocytic sarcoma (chloroma) presenting as a dumbbell tumor. 
  • Granulocytic sarcoma in the absence of myeloid leukemia. 
  • Growth inhibition by thymidine of leukemic HL-60 and normal human myeloid progenitor cells. 
  • Hairy cell leukemia-associated familial lymphoproliferative disorder: immunologic abnormalities in unaffected family members. 
  • Hemolytic transfusion reactions caused by failure of commercial antiglobulin reagents to detect complement. 
  • High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia. 
  • High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series. 
  • High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. 
  • Human leukemia antigens: partial isolation and characterization. 
  • IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. 
  • Impetiginous lesions in recurrent AML. 
  • Induction of differentiation in human myeloblastic leukemia ML-1 cells by heptachlor, a chlorinated hydrocarbon insecticide. 
  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. 
  • Levels of p53 protein increase with maturation in human hematopoietic cells. 
  • Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. 
  • Low serum thymic hormone levels in patients with chronic graft-versus-host disease. 
  • Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. 
  • Modulation of cell growth and differentiation by ceramide. 
  • Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. 
  • Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. 
  • Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 
  • Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. 
  • Myeloid neoplasms in the setting of chronic lymphocytic leukaemia/chronic lymphocytic leukaemia-like disease: a clinicopathological study of 66 cases comparing cases with prior history of treatment to those without. 
  • Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. 
  • Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. 
  • Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. 
  • Phase I-II trial of mitoxantrone in acute leukemia: an interim report. 
  • Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. 
  • Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. 
  • Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. 
  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). 
  • Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. 
  • Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Relationship of acivicin-induced monocytoid differentiation of human myeloid leukemia cells to acivicin-induced modulation of growth factor, cytokine, and protooncogene mRNA expression. 
  • Relationships between membrane antigens of human leukemic cells and oncogenic RNA virus structural components. 
  • Remission induction with L-asparaginase, vincristine, and prednisone in children with acute nonlymphoblastic leukemia. 
  • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. 
  • Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia. 
  • Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. 
  • SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. 
  • Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. 
  • Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. 
  • Telomerase activity in normal leukocytes and in hematologic malignancies. 
  • The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation. 
  • The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy. 
  • The role of EVI1 in myeloid malignancies. 
  • The use of umbilical cord blood in mismatched related and unrelated hemopoietic stem cell transplantation. 
  • Topoisomerase II levels during granulocytic maturation in vitro and in vivo. 
  • Translocation (X;19) with involvement of the inactive X chromosome in oligoblastic granulocytic leukemia. 
  • Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. 
  • Treatment of cutaneous granulocytic sarcoma in a patient with myelodysplasia. 
  • Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology